| Regimen change | Univariate | Multivariate | |||||
---|---|---|---|---|---|---|---|---|
Yes | No | Odds ratio | 95% CI | P value | Odds ratio | 95% CI | P value | |
n = 25 | n = 129 | |||||||
 Male, n (%) | 12 (48.0%) | 78 (60.5%) | 0.60 | 0.26–1.43 | 0.250 | 1.94 | 0.55–6.85 | 0.305 |
 BMI, kg/m2 (mean ± SD) | 19.1 ± 2.60 | 19.0 ± 2.66 | 1.01 | 0.86–1.19 | 0.858 |  |  |  |
CKD severity | ||||||||
 Mild | 10 (40.0%) | 83 (64.3%) | Reference | – | – | Reference | – | – |
 Moderate | 9 (36.0%) | 34 (26.4%) | 2.20 | 0.82–5.88 | 0.117 | 2.10 | 0.57–7.71 | 0.264 |
 Severe | 6 (24.0%) | 12 (9.3%) | 4.15 | 1.28–13.5 | 0.018 | 5.92 | 1.08–32.5 | 0.041 |
Underlying disease | ||||||||
 Liver damage | 2 (8.0%) | 10 (7.8%) | 1.03 | 0.21–5.04 | 0.966 |  |  |  |
Laboratory data | ||||||||
 Albumin, g/dL (mean ± SD) | 2.6 ± 0.8 | 3.2 ± 0.8 | 0.41 | 0.23–0.73 | 0.003 | 0.68 | 0.31–1.46 | 0.320 |
Treatment regimen, n (%) | ||||||||
 HREZ | 13 (52.0%) | 76 (58.9%) | 0.755 | 0.32–1.78 | 0.523 |  |  |  |
Adverse events | ||||||||
 Drug-induced hepatitis, n (%) | 14 (56.0%) | 8 (6.2%) | 19.3 | 6.63–55.9 | <0.001 | 35.6 | 8.70–145 | <0.001 |
 Cutaneous reaction, n (%) | 6 (24.0%) | 5 (3.9%) | 7.83 | 2.17–28.2 | 0.002 | 17.4 | 3.16–95.5 | 0.001 |